Erin O'Brien

The 2024 American Society of Clinical Psychopharmacology Annual Meeting brought together researchers and clinicians to engage in discussion, education, and dissemination of research findings and new methodologies.

An expert discusses this comorbidity, plus the effects of semaglutide and other GLP-1 agonists on this patient population.

Here are highlights from the week in Psychiatric Times.

The outcomes of this study are expected to inform the development of the upcoming PATHFINDER-52 phase 2b clinical trial.

Check out the latest results from the phase 3 CONNEX-X study.

Here are highlights from the week in Psychiatric Times.

The CDC suggests that disrupted access to ADHD medications may increase risk of overdose and injury.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Here are highlights from the week in Psychiatric Times.

What is new in research on schizophrenia?

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

Write to us now to be part of our series focused on stress and anxiety this month.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

An analysis presented at the ASCP Annual Meeting explored the safety and tolerability of the treatment for alcohol and tobacco use disorders.

A poster at the 2024 ASCP Annual Meeting shared data from 3 randomized clinical trials on the safety and tolerability of this treatment combination.

An expert discusses the potential of smartphones as treatment measurement tools at the 2024 ASCP Annual Meeting.

An expert discusses the role of cognition in bipolar disorder and the potential of modafinil as a treatment for it at the 2024 ASCP Annual Meeting.

An expert shares some lessons learned from prior research on the treatment and suggestions for a way forward at the 2024 ASCP Annual Meeting.

Attending the 2024 ASCP Annual Meeting? Be sure to catch these upcoming poster presentations.

Here are highlights from the week in Psychiatric Times.

The company has announced plans to submit the NDA in the first half of 2025.

“The findings emphasize the importance of monitoring the use of psychotropic combinations, particularly among vulnerable populations.”

Here are highlights from the week in Psychiatric Times.

What is new in research on postpartum depression?

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.